EA030961B1 - Применение производных глутаримидов для лечения эозинофильных заболеваний - Google Patents

Применение производных глутаримидов для лечения эозинофильных заболеваний Download PDF

Info

Publication number
EA030961B1
EA030961B1 EA201690798A EA201690798A EA030961B1 EA 030961 B1 EA030961 B1 EA 030961B1 EA 201690798 A EA201690798 A EA 201690798A EA 201690798 A EA201690798 A EA 201690798A EA 030961 B1 EA030961 B1 EA 030961B1
Authority
EA
Eurasian Patent Office
Prior art keywords
eosinophilic
compounds
general formula
syndrome
eosinophils
Prior art date
Application number
EA201690798A
Other languages
English (en)
Russian (ru)
Other versions
EA201690798A1 (ru
Inventor
Владимир Евгеньевич НЕБОЛЬСИН
Татьяна Александровна КРОМОВА
Анастасия Владимировна РЫДЛОВСКАЯ
Александр Григорьевич ЧУЧАЛИН
Original Assignee
Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Фарминтерпрайсез" filed Critical Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Publication of EA201690798A1 publication Critical patent/EA201690798A1/ru
Publication of EA030961B1 publication Critical patent/EA030961B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201690798A 2013-11-14 2014-11-12 Применение производных глутаримидов для лечения эозинофильных заболеваний EA030961B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
PCT/RU2014/000855 WO2015072893A1 (ru) 2013-11-14 2014-11-12 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Publications (2)

Publication Number Publication Date
EA201690798A1 EA201690798A1 (ru) 2016-08-31
EA030961B1 true EA030961B1 (ru) 2018-10-31

Family

ID=53057723

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201690798A EA030961B1 (ru) 2013-11-14 2014-11-12 Применение производных глутаримидов для лечения эозинофильных заболеваний
EA201990529A EA037447B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний
EA201891261A EA032940B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов
EA201891262A EA032955B3 (ru) 2013-11-14 2014-11-12 Применение производного глутаримида для лечения эозинофильных заболеваний

Family Applications After (3)

Application Number Title Priority Date Filing Date
EA201990529A EA037447B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний
EA201891261A EA032940B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов
EA201891262A EA032955B3 (ru) 2013-11-14 2014-11-12 Применение производного глутаримида для лечения эозинофильных заболеваний

Country Status (23)

Country Link
US (2) US9949962B2 (OSRAM)
EP (2) EP3069720B1 (OSRAM)
JP (4) JP2016540749A (OSRAM)
KR (2) KR102312013B1 (OSRAM)
CN (2) CN105722511B (OSRAM)
AU (2) AU2014349246C1 (OSRAM)
BR (1) BR112016010515B1 (OSRAM)
CA (1) CA2930231C (OSRAM)
CY (1) CY1122500T1 (OSRAM)
DK (1) DK3069720T3 (OSRAM)
EA (4) EA030961B1 (OSRAM)
ES (2) ES2836887T3 (OSRAM)
HU (1) HUE046671T2 (OSRAM)
IL (2) IL245429B (OSRAM)
LT (1) LT3069720T (OSRAM)
MX (2) MX386887B (OSRAM)
PL (2) PL3069720T3 (OSRAM)
PT (1) PT3069720T (OSRAM)
RU (1) RU2552929C1 (OSRAM)
SG (1) SG10201900504XA (OSRAM)
SI (1) SI3069720T1 (OSRAM)
UA (1) UA118687C2 (OSRAM)
WO (1) WO2015072893A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
KR102576903B1 (ko) 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여로 아토피성 피부염을 치료하는 방법
EP3725785B1 (en) * 2013-04-12 2024-04-10 Nebolsin, Vladimir Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
KR102927870B1 (ko) 2014-02-28 2026-02-19 리제너론 파아마슈티컬스, 인크. Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
EP4132571B1 (en) * 2020-04-07 2025-10-29 Hofseth Biocare ASA Salmonid oil compositions for use in the treatment of eosinophilic related inflammatory and respiratory conditions
MA58653B1 (fr) * 2020-06-26 2024-02-29 Valenta Intellekt Ltd Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024133A1 (en) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196767A (ja) * 1988-10-11 1990-08-03 Kyowa Hakko Kogyo Co Ltd ヒドロキサム酸誘導体
AU9134191A (en) * 1990-12-24 1992-07-22 Merrell Dow Pharmaceuticals Inc. Use of certain glutarimide derivatives in the treatment of depression and mania
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
ES2320638T3 (es) 2001-11-07 2009-05-27 Cytos Biotechnology Ag Disposicion ordenada de antigenos il-5, il-13 o eotasina, para el tratamiento de enfermedades alergicas con un componente eosinofilico.
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
DK3072525T3 (en) 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
EP3725785B1 (en) 2013-04-12 2024-04-10 Nebolsin, Vladimir Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024133A1 (en) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WOA1-2007000246 *

Also Published As

Publication number Publication date
EA037447B1 (ru) 2021-03-30
EP3466425A1 (en) 2019-04-10
WO2015072893A1 (ru) 2015-05-21
HUE046671T2 (hu) 2020-03-30
AU2014349246A9 (en) 2018-09-20
DK3069720T3 (da) 2019-11-25
PT3069720T (pt) 2019-12-02
US9949962B2 (en) 2018-04-24
EA032940B1 (ru) 2019-08-30
JP2020002152A (ja) 2020-01-09
SI3069720T1 (sl) 2020-02-28
MX2016006330A (es) 2016-09-06
AU2014349246C1 (en) 2019-02-21
EA201690798A1 (ru) 2016-08-31
CN105722511A (zh) 2016-06-29
EP3069720A8 (en) 2017-10-04
EA032955B3 (ru) 2020-02-27
KR102312013B1 (ko) 2021-10-15
ES2759530T3 (es) 2020-05-11
EA201990529A1 (ru) 2019-07-31
PL3466425T3 (pl) 2021-04-06
IL245429A0 (en) 2016-06-30
CN105722511B (zh) 2019-09-17
AU2014349246B2 (en) 2018-10-18
BR112016010515B1 (pt) 2022-09-27
JP6758677B2 (ja) 2020-09-23
LT3069720T (lt) 2020-01-10
JP2019214606A (ja) 2019-12-19
PL3069720T3 (pl) 2020-05-18
EP3069720A1 (en) 2016-09-21
AU2018264084B2 (en) 2020-05-14
KR20200053639A (ko) 2020-05-18
EA201891261A1 (ru) 2018-10-31
EP3069720A4 (en) 2017-06-21
ES2836887T3 (es) 2021-06-28
EA201891262A1 (ru) 2018-10-31
MX386887B (es) 2025-03-19
EP3069720B1 (en) 2019-10-30
AU2018264084C1 (en) 2020-08-27
UA118687C2 (uk) 2019-02-25
EA032955B1 (ru) 2019-08-30
JP2016540749A (ja) 2016-12-28
CA2930231A1 (en) 2015-05-21
US10220029B2 (en) 2019-03-05
MX365781B (es) 2019-06-13
MX2019006881A (es) 2019-08-01
RU2552929C1 (ru) 2015-06-10
KR20160078400A (ko) 2016-07-04
JP2019055953A (ja) 2019-04-11
RU2013150861A (ru) 2015-05-20
US20180104230A1 (en) 2018-04-19
IL271352A (en) 2020-01-30
IL271352B (en) 2021-04-29
AU2014349246A1 (en) 2016-05-19
AU2018264084A1 (en) 2018-12-06
CY1122500T1 (el) 2021-01-27
EP3466425B1 (en) 2020-10-07
JP6589251B2 (ja) 2019-10-16
IL245429B (en) 2020-02-27
KR102312294B1 (ko) 2021-10-15
SG10201900504XA (en) 2019-02-27
CN110200968A (zh) 2019-09-06
CA2930231C (en) 2022-06-14
US20160279114A1 (en) 2016-09-29
BR112016010515A2 (OSRAM) 2017-08-08

Similar Documents

Publication Publication Date Title
RU2552929C1 (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
WO2013170758A1 (zh) 含稠环结构的苯甲酰胺类化合物及其作为抗肿瘤药物应用
JP2017525765A (ja) 新規イミノニトリル誘導体
US20240317762A1 (en) Phthalazinone-based parp-1 inhibitors
CN116041418A (zh) 羟脯氨酰基-丝氨酸化合物及其制备方法和应用
HK40007097A (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
HK40007097B (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
CN118515598A (zh) 甲异靛的多晶型和甲异靛的改进制剂
HK1224930A1 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
WO2020087565A1 (zh) 吲唑类激酶抑制剂及其用途
HK1224930B (zh) 包含戊二酰亚胺衍生物的药物组合物及其用於治疗嗜酸细胞性疾病的用途
RU2562773C2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

QB4A Registration of a licence in a contracting state
PC4A Registration of transfer of a eurasian patent by assignment